BMO Capital Sees Almost 300% Upside On Centessa Stock

 

• BMO Capital has initiated coverage on Centessa Pharmaceuticals plc 
  CNTA+19.1%+ Free Alerts
   with a price target of $19 (293% upside), and an Outperform rating.
• The analyst writes that ZF874 is a differentiated oral therapy as it addresses the root cause of AATD. Early ZF874 data (N=2) demonstrated therapeutic efficacy in patients, but liver toxicity was also flagged.
• Centessa is currently trying to identify an optimal dose that circumvents the liver toxicity while maintaining efficacy. The data readout is expected in 2H22.
• The analyst notes that the hemophilia program with potential FDA approval in 2026 could drive short-term upside.
• SerpinPC is differentiated against most approved/investigational hemophilia treatments as it doesn’t trigger thrombosis and comes with convenient dosing. 
• An open-label extension study readout is planned for 4Q22.

https://www.benzinga.com/general/biotech/22/06/27769833/this-analyst-sees-almost-350-upside-on-centessa-stock